PFE : Summary for Pfizer, Inc. Common Stock - Yahoo Finance

U.S. Markets closed

Pfizer Inc. (PFE)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
34.16-0.02 (-0.06%)
At close: 4:01PM EDT

34.12 -0.04 (-0.12%)
After hours: 5:00PM EDT

People also watch
MRKJNJJPMGEINTC
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close34.18
Open34.06
Bid0.00 x
Ask0.00 x
Day's Range33.97 - 34.26
52 Week Range29.41 - 37.39
Volume18,336,548
Avg. Volume25,216,455
Market Cap203.43B
Beta1.04
PE Ratio (TTM)29.12
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.28 (3.76%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects?
    Motley Fool2 hours ago

    Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects?

    AstraZeneca, Bristol-Myers Squibb, and Pfizer receive good news from the real world.

  • Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe
    Zacks6 hours ago

    Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

    Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

  • Barrons.com7 hours ago

    [$$] Could Pfizer Make Cash Bid for Bristol-Myers?

    Credit Suisse One of the most common topics of discussion in our investor meetings remains the question around whether Pfizer or another biopharma company may be interested in acquiring Bristol-Myers Squibb in the next nine-12 months, given some of the challenges Bristol-Myers is facing and the activist involvement in the name. To supplement our previous work, our HOLT [proprietary Credit Suisse platform] colleagues have now taken a look at the possibility of Pfizer buying Bristol-Myers from a HOLT perspective and do see the deal as providing an opportunity for value-creation.